Three Frameworks
HELMER 7 POWERS (Market, Strategy, Profit):
These may be more interesting when embedded in their framework: haven't studied yet.
TEN TYPES OF INNOVATION Keeley 2013
https://www.amazon.com/Ten-Types-Innovation-Discipline-Breakthroughs/dp/1118504240
May be co branded with Deloitte
https://www.hypeinnovation.com/blog/using-the-ten-types-of-innovation-framework
TEN OR TWELVE TYPES OF HC VALUE - Lou Garrison Jr
https://www.jmcp.org/doi/pdf/10.18553/jmcp.2020.26.4.400
##
I stumbled into some blogs on history of sequencing tech and someone used HELMER 7 POWERS to frame a history of ILMN tech strategy and barriers.
##
I was reading Nephron's 14-page article about AGBT 2024, with the title:
AGBT: ILMN is Under Siege from All Sides (Jack Meehan, February 8, 2024)
(Subscription)
There, Nephron hosted a session with Keith Robison of OMICS OMICS.
##
AGBT 2024 was a poor showing by Illumina in that it was virtually non-existent with investors. Unlike prior years, Illumina did not have any new product introductions or investor events. Illumina’s lack of promotional presence was in stark contrast to the sequencing competition. The company was a “contributing sponsor” (vs Ultima at Gold, Element a Silver sponsor amongst others, and PacBio a bronze sponsor amongst others). As such, the company did not have a dedicated speaking slot to promote its products to the conference attendees.
One of the four Nephron events we hosted was a session with Keith Robison (Omics Omics blog) on Tuesday, who helped to shine a longer-term perspective on the NGS industry. ABI was the initial dominant sequencing provider with Sanger, though they ultimately got leapfrogged by Illumina for a number of reasons.
https://omicsomics.blogspot.com/
The history of the industry should serve as a cautionary tale for Illumina as the company makes hard decisions around retaining top talent and cutting costs. The sequencing newcomers are going to make the most of whatever opportunity to jump in that Illumina gives them. Illumina’s track record with regulatory oversight of M&A means internal investment should get prioritized. We think Illumina needs to innovate more (vs iterate) when it comes to R&D.
##
There, at omics omics, an article on ILMN's "Moats Past and Present."
https://omicsomics.blogspot.com/2024/01/on-illuminas-moats-past-present.html
That led to an article at ASEQ NEWSLETTER by Nava Whiteford. It's apparently part 7 of 8 of a review by Nava, of a different blog called CENTURY OF BIOLOGY. CENTURY apparently wrote an article called "Illumina: The Measurement Monopoly," by someone named Elliott. For example, number 7 of 8 is here:
https://aseq.substack.com/p/everything-wrong-with-illumina-the-672
Where she talks about Elliott using the HELMERS SEVEN POWERS framework.
Here is CENTURY of BIOLOGY, which Nava was critiqueing (I'll come right back to HELMERS).
Here is Century of Biology by Elliot Hersberg
Here is its Illumina article at Century: "The Measurement Monopoly". 30pp as PDF.
https://centuryofbio.com/p/illumina
In the long article, here's how Elliott leads into Helmer 7 Powers:
Strategic analysis
After years of successful active equity investing and business consulting, Hamilton Helmer developed a “simple but not simplistic” framework for analyzing strategic competitiveness. In 2016, Helmer shared these insights with the world in a book called 7 Powers: The Foundations of Business Strategy. This book has become a cornerstone in the field of Strategy, which Helmer defines as “the study of the fundamental determinants of potential business value.”
##
Two long blogs on HELMER are here:
https://tyastunggal.com/p/7-powers-the-foundations-of-business
https://jacobwallenberg.medium.com/notes-on-7-powers-b0f107663501
My downloads of all the above are here:
2023 Wallenbergs Book Notes on HELMER 7 POWERS (16pp).pdf
2023 TYAS TYNGAL 30pp on HELMERS 7 POWERS.pdf
2024 NEPHRON 08 14p AGBT ILMN is Under Siege from All Sides.pdf
2024 CEntury of Biology ILMN Measurement Monopoly 25pp.pdf
2024 ASEQ NEWSLETTER 0107 Pt 7 of 8 re ILMN at CENT of BIOL.pdf
2024 OMICS OMICS 0129 On ILMN MOats (re ASEQ NEWSLTR).pdf
The article details Illumina's journey to becoming a dominant force in the genomics industry, focusing on its innovative DNA sequencing technologies and strategic business moves. It highlights Illumina's founding, its pivotal acquisition of Solexa to advance next-generation sequencing (NGS), and how it established a monopoly in genomics measurement through strategic patents, technological advancements, and a focus on scale and branding. The piece also discusses the broader impact of Illumina's work on biotech and genomics, suggesting that the company's success story offers valuable lessons for entrepreneurs and investors in the technology and biology sectors.
On the two adjacent articles OMICS "On Monopoly" and ASEQ (critique).
The two articles provide critical perspectives and counterarguments to the original article's portrayal of Illumina's dominance in the genomics industry. They dissect Illumina's claimed competitive advantages, such as cornered resources, switching costs, network economies, scale economies, and branding, offering a more nuanced view.
One article argues that Illumina's success is primarily due to its intellectual property and not necessarily the other factors mentioned. It also challenges the notion of switching costs, suggesting genome centers are keen on adopting new technologies. The analysis further questions the impact of network and scale economies and Illumina's pricing power, suggesting that the landscape is evolving with new competitors.
These critiques suggest that while Illumina has been a dominant player, the dynamics of the genomics industry are changing, and there may be more room for competition than previously thought.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.